ImmunoCellular suspends Phase III GBM trial of ICT-107 for lack of cash

ImmunoCellular Therapeutics Ltd. (NYSE-M:IMUC) suspended enrollment for financial reasons in its Phase III trial evaluating ICT-107 to treat newly diagnosed glioblastoma multiforme (GBM). The company said it is unable at this time to secure sufficient additional financial resources to complete the trial. ImmunoCellular said it will work to ensure that patients already enrolled and receiving treatment in the trial can be appropriately supported and followed.

The company is seeking to partner or out-license ICT-107 to focus on its Stem-to-T-cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. It is also evaluating strategic options for its immuno-oncology R&D pipeline, which may include a merger, reorganization or sale...